Challenges and opportunities when transitioning
from in vivo gene replacement to in vivo CRISPR/
Cas9 therapies – a spotlight on hemophilia
In vivo gene editing in liver tissues may be able to rescue patients younger than 18 years who are not eligible for gene replacement therapies, with hemophilia as a prime example